Products for Research Use Only

Leflunomide-d4

CAT: 0804-HY-B0083SSize: 500 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0083SSize:500 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Leflunomide-d4 (HWA486-d4) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent[1][2].
CAS Number
1189987-23-2
UNSPSC
12352005
Hazard Statement
H302+H312+H332-H315-H319
Target
Dihydroorotate Dehydrogenase
Type
Isotope-Labeled Compounds
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
C(NC1=C(C(=C(C(F)(F)F)C(=C1[2H])[2H])[2H])[2H])(=O)C2=C(C)ON=C2
Molecular Formula
C12H5D4F3N2O2
Molecular Weight
274.23
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P501
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Davis JP, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996 Jan 30;35 (4) :1270-3.|[3]Xu X, et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem. 1995 May 26;270 (21) :12398-403.|[4]Fox RI, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999 Dec;93 (3) :198-208.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported